Radiobiology

The Radiosurgery Society® Establishes Residents Association to Optimize Educational Experience and Foster Future Leaders in SRS/SBRT

Retrieved on: 
Wednesday, May 19, 2021
Medicine, Clinical medicine, Medical specialties, Neurosurgery, Radiobiology, Radiosurgery, Stereotactic surgery, Radiation therapy, SRS, Radiation oncologist, Jay Loeffler

"\nRSSRA members have access to an array of opportunities for education, training, networking, and mentorship in the fields of SRS/SBRT that maximize both individual and group participation.

Key Points: 
  • "\nRSSRA members have access to an array of opportunities for education, training, networking, and mentorship in the fields of SRS/SBRT that maximize both individual and group participation.
  • Through the association, residents also have opportunities to do research, publish, present, and apply for various awards.
  • RSS Membership for residents and members-in-training is only $35/year.\nThe Radiosurgery Society (RSS) a non-profit, independent, multi-disciplinary organization of surgeons, radiation oncologists, physicists, and allied professionals, who are dedicated to advancing the science and clinical practice of radiosurgery.
  • Originally formed in 2002 and becoming 501(c)(6) in 2008, the Radiosurgery Society ( http://www.therss.org ) supports its members who perform stereotactic body radiotherapy and radiosurgery in hospitals and freestanding centers throughout the world.\n'

Institut Bergonié and Seven and Eight Biopharmaceuticals Inc. Announce the First Patient Treated in the AGADIR Study of BDB001 in Combination with Atezolizumab and Immunogenic Radiotherapy in Solid Tumors

Retrieved on: 
Tuesday, May 18, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Radiobiology, TLR7, Radiation therapy, Treatment of cancer, Physical sciences, Natural sciences, Physics, Seven and Eight Biopharma, Institut Bergonié, SEVEN AND EIGHT BIOPHARMA, INSTITUT BERGONIé

Institut Bergoni\xc3\xa9 is the sponsor of the AGADIR Phase II protocol, \xe2\x80\x9cAtezolizumab combined with BDB001 and Immunogenic Radiotherapy in patients with advanced solid tumors\xe2\x80\x9d ( NCT03915678 ), which will enroll patients with difficult-to-treat solid tumors across 10 clinical centers in France.

Key Points: 
  • Institut Bergoni\xc3\xa9 is the sponsor of the AGADIR Phase II protocol, \xe2\x80\x9cAtezolizumab combined with BDB001 and Immunogenic Radiotherapy in patients with advanced solid tumors\xe2\x80\x9d ( NCT03915678 ), which will enroll patients with difficult-to-treat solid tumors across 10 clinical centers in France.
  • BDB001 is a first-in-class Toll-like receptor 7/8 (TLR7/8) agonist, which is delivered intravenously, allowing for broader treatment of solid tumors compared to intratumoral TLR agonists in development.\n\xe2\x80\x9cWe are delighted to begin this clinical study with BDB001.
  • We offer dedicated inpatient and outpatient cancer treatment including radiotherapy and hemotherapy as well as a number of related support services.
  • As a non-profit private hospital dedicated to public service, we have a three-fold mission: patient care, research and oncology education.

Disinfection Technology Firm Violet Defense Partners With Edison Award-Winner ecoSPEARS

Retrieved on: 
Tuesday, May 18, 2021
Pollution, Ultraviolet radiation, Hygiene, Medical specialties, Electromagnetic radiation, Radiobiology, Sterilization, Ultraviolet germicidal irradiation, Ultraviolet, Persistent organic pollutant, Disinfectant, Polychlorinated biphenyl

"This exciting step for Violet Defense means that we can successfully utilize our patented UV technology to provide cleaner water, air, and surfaces throughout the world.

Key Points: 
  • "This exciting step for Violet Defense means that we can successfully utilize our patented UV technology to provide cleaner water, air, and surfaces throughout the world.
  • "\nViolet Defense uses UV disinfection to protect everyday spaces from harmful pathogens by killing up to 99.9% of E. coli, Salmonella, MRSA, C.
  • Violet Defense\'s technology is the only known Pulsed Xenon solution that can be installed into a room full-time, creating a continuous way to address disinfection needs of all types of settings.
  • ecoSPEARS eliminates toxins like PCBs, dioxins, and other persistent organic pollutants (POPS) from the environment utilizing non-thermal and non-combusting remediation technology developed by NASA.

iCAD Announces Educational Webinar Featuring Leading Global Experts Discussing New Multidisciplinary Approach for Treating Brain Tumors, May 25

Retrieved on: 
Monday, May 17, 2021
Intraoperative radiation therapy, Radiation therapy, Radiobiology, Medical physics, Brain tumor, Nuclear physics, Physical sciences, Medicine

The free webinar, titled \xe2\x80\x9cIORT: Can a New Multidisciplinary Approach Make a Difference in Treating Brain Tumors?\xe2\x80\x9d will take place Tuesday, May 25, 2021, from 12:00 to 1:00 pm EDT.

Key Points: 
  • The free webinar, titled \xe2\x80\x9cIORT: Can a New Multidisciplinary Approach Make a Difference in Treating Brain Tumors?\xe2\x80\x9d will take place Tuesday, May 25, 2021, from 12:00 to 1:00 pm EDT.
  • \xe2\x80\x9cCurrent treatment methods are often limited by a high risk of toxicity from radiation; however, Xoft Brain IORT is a multidisciplinary treatment that is gaining recognition as a feasible option for treating brain tumors.
  • The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements.
  • The Company is under no obligation to provide any updates to any information contained in this release.

Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer

Retrieved on: 
Monday, May 17, 2021
Medicine, Clinical medicine, Health sciences, Neurosurgery, Radiobiology, Radiation therapy, Radioactivity, Stereotactic surgery, Therapy, Cancer

GC4711 is a selective small molecule dismutase mimetic being developed to increase the anti-cancer effect of radiation.

Key Points: 
  • GC4711 is a selective small molecule dismutase mimetic being developed to increase the anti-cancer effect of radiation.
  • Secondary endpoints include progression-free survival (PFS), locoregional control (LRC), time to distant metastases (TDM) and surgical resection, in addition to safety.
  • GC4711 is in development specifically to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT).
  • A pilot Phase 1/2 trial of GC4419 in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC) has completed enrollment and reported updated results, with follow-up ongoing.

American Shared Hospital Services Reports First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 13, 2021
Medicine, Clinical medicine, Health sciences, Neurosurgery, Radiobiology, Medical physics, Radiosurgery, Therapy, Stereotactic surgery, Radiation therapy, Proton therapy, fis

b'SAN FRANCISCO, CA, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the first quarter of fiscal 2021 ended March 31, 2021.\nTotal revenue in the first quarter was $4,364,000, a decrease of 4.5% when compared with the first quarter of 2020.\xc2\xa0Proton therapy revenue was $1,531,000, a decrease of 8.7% when compared with the first quarter of 2020.

Key Points: 
  • b'SAN FRANCISCO, CA, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the first quarter of fiscal 2021 ended March 31, 2021.\nTotal revenue in the first quarter was $4,364,000, a decrease of 4.5% when compared with the first quarter of 2020.\xc2\xa0Proton therapy revenue was $1,531,000, a decrease of 8.7% when compared with the first quarter of 2020.
  • \xe2\x80\x9cOur financial results have begun to reflect the impact of the year end asset write-downs and the financial restructuring with Fifth Third Bank that we announced in early April.
  • This is in addition to our focus on reducing selling and administrative expenses, which decreased 10.5% in the first quarter.
  • To participate, please call 1 (877) 317-6789 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.

Science Translational Medicine Article Shows Galera’s Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors

Retrieved on: 
Wednesday, May 12, 2021
Physical sciences, Antioxidants, Radiobiology, Oxidoreductases, Enzymes, Superoxide dismutase mimetics, Chemistry, Natural sciences, Radiation therapy, Dismutase, Mucositis, Radiation

The synergy between the mimetic and radiotherapy increased with larger daily doses (\xe2\x80\x9cfractions\xe2\x80\x9d) of radiation.

Key Points: 
  • The synergy between the mimetic and radiotherapy increased with larger daily doses (\xe2\x80\x9cfractions\xe2\x80\x9d) of radiation.
  • Moreover, in the range of fraction sizes typical of SBRT, the combination ablated many of the tumors.
  • In addition, as previously published, the authors report that by removing the superoxide, the dismutase mimetics protected normal cells from radiation toxicity.
  • Galera\xe2\x80\x99s lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a selective small molecule dismutase mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM).

Two Day Online Seminar: Radiation Sterilization of Medical Products - Beyond the Basics, August 12-13, 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021
Health, Medical devices, Other Health, Health sciences, Health, Articles, Radiobiology, Pharmaceutical industry, Electron beam, Hygiene, Microbiology, Sterilization, Bioburden, Validation, Compulsory sterilization

b'The "Radiation Sterilization of Medical Products - Beyond the Basics" conference has been added to ResearchAndMarkets.com\'s offering.\nThis two-day highly interactive course will cover all aspects of radiation sterilization validation, materials selection and processing implementation.

Key Points: 
  • b'The "Radiation Sterilization of Medical Products - Beyond the Basics" conference has been added to ResearchAndMarkets.com\'s offering.\nThis two-day highly interactive course will cover all aspects of radiation sterilization validation, materials selection and processing implementation.
  • This workshop has been designed to help attendees learn the ins and outs of all the radiation modalities, materials selection, and validation of the sterilization process per ISO 11137.\nAdditionally, 483 case studies will explore how to avoid the operational and legal issues that arise from nonconformance with regulators (FDA) and auditors.\nUpon completing this course on radiation sterilization, participants will:\nUnderstand how to select product polymer materials for optimal product performance after radiation sterilization processing.\nKnow how to complete an optimal validation test design - inclusive of dose, dosimetry, sample size, accelerated ageing, ASTM standards, and thermal analysis.\nUnderstand the effect of product design and assembly on bioburden, product safety and the success in executing the validation journey.\nUnderstand all the foundations of a successful radiation sterilization program - materials, bioburden, validation, maintenance of validation.\nUnderstand the impacts of all regulatory guidances on the radiation sterilization process.\nUnderstand where companies miss the mark in triggering, investigating and executing bioburden action levels and quarterly sterilization audits.\nThis course is designed for medical device, biologic products, and pharmaceutical professionals who desire to get a complete understanding of the validation and use of radiation sterilization for their products.\nThe following personnel will benefit from the course:\n'

ChargeTech Introduces CleanCharge Line: Chemical-Free Disinfection Products for Classrooms and Enterprises

Retrieved on: 
Wednesday, May 12, 2021
Mobile, Wireless, Hardware, Office Products, Technology, Other Education, Infectious diseases, University, Primary, Secondary, Education, Retail, Medical Supplies, Other Technology, Health, Physical sciences, Computer architecture, Chemistry, Ultraviolet radiation, Hygiene, Laptops, Radiobiology, Sterilization, Ultraviolet germicidal irradiation, Disinfectant, Ultraviolet, Chromebook

\xe2\x80\x9cCleanCharge by ChargeTech is a new collection of antimicrobial and UV disinfection products that are specifically designed to improve the health and safety of today\xe2\x80\x99s classrooms and workplaces.

Key Points: 
  • \xe2\x80\x9cCleanCharge by ChargeTech is a new collection of antimicrobial and UV disinfection products that are specifically designed to improve the health and safety of today\xe2\x80\x99s classrooms and workplaces.
  • Each shelf can Charge, Store and Disinfect up to 10 laptops, Chromebooks, tablets, phones, ChargeTech battery packs and other similar sized electronic devices.
  • The dividers can easily be removed and reconfigured for optimal disinfection of a wide variety of items.
  • The current generation (2.0) comes with a highly-reflective stainless steel interior for improved UV-C exposure.\n\xe2\x80\x9cOur CleanCharge products are adaptable to accommodate electronic devices of all types and sizes,\xe2\x80\x9d said ChargeTech CEO John Cappetta.

American Shared Hospital Services Announces First Quarter 2021 Earnings Conference Call

Retrieved on: 
Monday, May 10, 2021
Medicine, Clinical medicine, Health sciences, Neurosurgery, Radiobiology, Medical physics, Radiation therapy, Radioactivity, Radiosurgery, Stereotactic surgery, Proton therapy, Therapy

b'San Francisco, CA, May 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its first quarter 2021 financial results on Thursday, May 13th, 2021 at 1:00pm EST / 10:00am PST.

Key Points: 
  • b'San Francisco, CA, May 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its first quarter 2021 financial results on Thursday, May 13th, 2021 at 1:00pm EST / 10:00am PST.
  • The first quarter 2021 financial results press release will be issued premarket the morning of Thursday, May 13th, 2021.\nTo participate, please call 1 (877) 317-6789 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
  • A simultaneous webcast of the call may be accessed through the Company\'s website,\xc2\xa0www.ashs.com, or\xc2\xa0at www.streetevents.com for institutional investors.\nA replay of the call will be available at 1 (877) 344-7529, access code 10156388, through May 20, 2021.\nAbout American Shared Hospital Services (NYSE American: AMS)\nAmerican Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services.
  • The Company also offers proton therapy, and the latest IGRT, IMRT and MR/LINAC systems.